Allogeneic engineered T-cell immunotherapy

Class

Allogeneic engineered T-cell immunotherapy (donor-derived HSPC + high-purity regulatory T-cell + conventional T-cell graft composition, adjunct to hematopoietic stem cell transplant)

Pathway

Treg-mediated immune modulation to prevent graft-versus-host disease while preserving graft-versus-leukemia effect

Notes

original target text: Allogeneic engineered T-cell immunotherapy (donor-derived HSPC + high-purity regulatory T-cell + conventional T-cell graft composition, adjunct to hematopoietic stem cell transplant)

Allogeneic hematopoietic stem cell transplant (HSCT) uses donor blood-forming cells to replace a patient's marrow, often to treat blood cancers. Donor T cells within the graft can attack the leukemia (graft-versus-leukemia, GVL), but they can also attack the recipient's own healthy tissues, causing graft-versus-host disease (GVHD), a major cause of illness and death after transplant. Regulatory T cells (Tregs) are a specialized T-cell subset whose physiological role is to dampen immune attack against the body's own tissues. This mechanism engineers the donor graft itself, combining donor blood stem cells (HSPCs), a high-purity population of Tregs, and a defined dose of conventional T cells, rather than relying solely on drugs given after transplant to control immune activity. The rationale is to let Tregs restrain the harmful, tissue-damaging component of donor T-cell activity while allowing the beneficial anti-leukemia activity to proceed, potentially reducing dependence on broad immunosuppressive medications that carry their own infection and toxicity risks. This approach is relevant across hematologic malignancies treated with allogeneic transplant, where balancing GVHD prevention against preservation of GVL is a central clinical challenge.